Jim Z. Li - Concepedia

Author

Jim Z. Li

Pfizer (United States)ORCID

Also Known As

Jim Li, Jim Z Li, Jim Z. Li

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Pharmerit (United States)University of Southern California Western Michigan University Memorial Sloan Kettering Cancer Center

About

Jim Z. Li is an author at Pfizer (United States) specializing in medicine, infection control, and antimicrobial resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	428
2	Health Sciences	5	5	216
3	Public Health	3	3	52
4	Emergency Medicine	2	2	33
5	Epidemiology	1	1	19

Jim Z. Li

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman, Journal of Clinical Oncology	2005	1.6K
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors Matthew H. Kulke, Heinz‐Josef Lenz, Neal J. Meropol, Journal of Clinical Oncology	2008	618
Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial David Cella, Jim Z. Li, Joseph C. Cappelleri, Journal of Clinical Oncology	2008	129
Patient Reported Differences in Dry Eye Disease between Men and Women: Impact, Management, and Patient Satisfaction Debra A. Schaumberg, Miki Uchino, William G. Christen, PLoS ONE	2013	121
Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China Warren Stevens, Desi Peneva, Jim Z. Li, BMC Health Services Research	2016	106
Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA) Kamal M.F. Itani, John A. Weigelt, Jim Z. Li, International Journal of Antimicrobial Agents Soft Tissue InfectionsAntimicrobial SusceptibilityIntravenous TreatmentAntibioticsHealth Sciences	2005	105
Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease Shiao Hui Melissa Liew, Kelly K. Nichols, Karen J. Klamerus, Ophthalmology Janus Kinase InhibitorOcular DiseaseOphthalmologyMedicineReceptor Tyrosine Kinase	2012	87
Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: A plea for implementation of early switch and early discharge criteria Christian Eckmann, W. Lawson, Dilip Nathwani, International Journal of Antimicrobial Agents Mrsa-targeted TherapyOral MedicineEarly SwitchDermatologyDrug Resistance	2014	58
Prevalence, Comorbidities, and Risk Factors of Erectile Dysfunction: Results from a Prospective Real‐World Study in the United Kingdom Jim Z. Li, Terence A. Maguire, Kelly H. Zou, International Journal of Clinical Practice	2022	54
Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan Shu‐Ting Chen, Shih‐Ting Huang, Wen‐Yi Shau, BMC Cardiovascular Disorders	2019	42

Page 1